Stifel analyst Paul Matteis initiated coverage of Sionna Therapeutics (SION) with a Buy rating and $32 price target Sionna is a biotech company focused on developing novel treatment regimens for cystic fibrosis, working on a novel mechanism-of-action in NBD1 stabilization, the analyst tells investors in a research note. The firm says the company “has checked all the boxes one would want to see” for a preclinical company in cystic fibrosis. It likes the stock risk/reward into 2026 proof-of-concept data.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SION:
- Sionna Therapeutics: Promising NBD1 Stabilizers Poised to Challenge Vertex in the $11 Billion CF Market
- Sionna Therapeutics: Innovative NBD1 Stabilizers and Strategic Synergies Drive Buy Rating
- Opening Day: AI mobility provider, steel veteran make trading debuts